TABLE 2.
Association of demographic factors with awareness, use and discussion with doctors of incretin‐based pharmacotherapy.
| Gender | Education | Race | Financial security | Comorbidities | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | Women (n = 123) | Men (n = 67) | Less than bachelors (n = 120) | Bachelors or higher (n = 70) | White (n = 121) | Black/African American (n = 51) | Low (n = 62) | High (n = 128) | Yes (n = 155) | No (n = 35) | |
| Aware of incretin‐based pharmacotherapy | |||||||||||
| Yes | 160 (84%) | 104 (85%) | 56 (84%) | 93 (77%)** | 67 (96%) | 105 (87%) | 40 (78%) | 50 (81%) | 110 (86%) | 137 (88%)* | 23 (66%) |
| No | 30 (16%) | 19 (15%) | 11 (16%) | 27 (23%) | 3 (4%) | 16 (13%) | 11 (22%) | 12 (19%) | 18 (14%) | 18 (12%) | 12 (34%) |
| Ever used incretin‐based pharmacotherapy | |||||||||||
| Yes | 28 (15%) | 22 (18%) | 6 (9%) | 15 (13%) | 13 (19%) | 18 (15%) | 8 (16%) | 11(18%) | 17 (13%) | 27 (17%) | 1 (3%) |
| No | 162 (85%) | 101 (82%) | 61 (91%) | 105 (88%) | 57 (81%) | 103 (85%) | 43 (84%) | 51(82%) | 111 (87%) | 128 (83%) | 34 (97%) |
| Discussed incretin‐based pharmacotherapy with doctor | |||||||||||
| Yes | 62 (33%) | 47 (38%)* | 15 (22%) | 32 (27%)* | 30 (43%) | 44 (36%) | 15 (29%) | 23 (37%) | 39 (30%) | 31 (24%)** | 4 (11%) |
| No | 128 (66%) | 76 (62%) | 52 (78%) | 88 (63%) | 40 (57%) | 77 (64%) | 36 (71%) | 39 (63%) | 89 (70%) | 97 (76%) | 31 (89%) |
*p < 0.05, **p < 0.01, ***p < 0.001.